May 2011 Newsletter

May 23, 2011:

US Market for Retina Treatments Continues to Grow Due to Increased Use of Anti-VEGFs

The number of IVT injections in the US continued to climb, as Avastin’s share declined somewhat and Lucentis’ share increased.

May 23, 2011:

ARVO Meeting Examines Key Clinical Trials in Retinal Pharma and Spotlights Regenerative Medicine

The Association of Research in Vision and Ophthalmology (ARVO) offered a window on cutting edge eye science and medicine plus clinical trials updates for retinal agents.

CATT, Lucentis & Avastin
VEGF Trap-Eye
Other AMD & DME Clinical Trials
Investigational Glaucoma Therapies
Dry AMD
Genetics & Genomics
Nanotechnology & Regenerative Medicine

May 23, 2011:

Investigational Glaucoma Pharmaceuticals at ARVO

A number of scientific posters explored investigational glaucoma therapeutics.

May 23, 2011:

Market Scope Introduces New Online Survey Application

Practice Scope is Market Scope’s new online survey application designed to bring more value to survey participants, improve response rates, and ultimately improve the scope and precision of our reports on the ophthalmic market.

May 23, 2011:

Annual Global IOL Revenue Growth Forecast at 7.6 Percent through 2016

Our new 2011 Comprehensive Report on the Global IOL Market forecasts significant revenue growth in the next five years.

May 23, 2011:

May 2011 News Briefs

This month's news includes the latest from Alcon, Novartis, WaveTec Vision Systems, Merck, Inspire Pharmaceuticals, iCo Therapeutics, Akorn, and Advanced Vision Research.

Social media